Ultragenyx (RARE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ultragenyx (RARE) has a cash flow conversion efficiency ratio of -5.658x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-91.42 Million) by net assets ($16.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ultragenyx - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Ultragenyx's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read RARE total liabilities for a breakdown of total debt and financial obligations.
Ultragenyx Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ultragenyx ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Computer Age Management Services Limited
NSE:CAMS
|
0.030x |
|
AVI LTD (UNSP.ADR)/5
F:IZ60
|
N/A |
|
King’s Town Bank
TW:2809
|
0.025x |
|
Domain Holdings Australia Ltd
AU:DHG
|
0.049x |
|
WisdomTree Inc.
NYSE:WT
|
0.129x |
|
Anhui Guangxin Agrochemical Co Ltd
SHG:603599
|
0.011x |
|
China Resources Chemical Innovative Materials Co. Ltd.
SHE:301090
|
-0.030x |
|
Anywhere Real Estate Inc
NYSE:HOUS
|
0.078x |
Annual Cash Flow Conversion Efficiency for Ultragenyx (2011–2024)
The table below shows the annual cash flow conversion efficiency of Ultragenyx from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Ultragenyx stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $262.30 Million | $-414.19 Million | -1.579x | +8.40% |
| 2023-12-31 | $275.41 Million | $-474.81 Million | -1.724x | -59.72% |
| 2022-12-31 | $352.49 Million | $-380.46 Million | -1.079x | -194.00% |
| 2021-12-31 | $922.56 Million | $-338.69 Million | -0.367x | -220.53% |
| 2020-12-31 | $1.15 Billion | $-132.22 Million | -0.115x | +78.32% |
| 2019-12-31 | $653.76 Million | $-345.38 Million | -0.528x | -10.71% |
| 2018-12-31 | $608.91 Million | $-290.57 Million | -0.477x | +27.92% |
| 2017-12-31 | $383.45 Million | $-253.84 Million | -0.662x | -94.92% |
| 2016-12-31 | $473.97 Million | $-160.97 Million | -0.340x | -70.20% |
| 2015-12-31 | $531.09 Million | $-105.98 Million | -0.200x | +17.32% |
| 2014-12-31 | $184.94 Million | $-44.63 Million | -0.241x | +61.24% |
| 2013-12-31 | $50.11 Million | $-31.20 Million | -0.623x | -319.98% |
| 2012-12-31 | $84.34 Million | $-12.50 Million | -0.148x | +72.91% |
| 2011-12-31 | $10.64 Million | $-5.83 Million | -0.547x | -- |
About Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth fac… Read more